The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

Table 6 PROGRESS 10 highest enrolling countries and 10 highest drotrecogin alfa (activated) using countries

			DrotAA-treated patients
Country	Number of sites	Enrolled patients, n (% overall) (n = 12,492)	n, (% of total DrotAA patients) [Overall rank] (n = 882)	Within-country DrotAA use, % (DrotAA patients/Total patients) [Rank]
Germany*	17	1810 (14.5)	98 (11.1) [3]	5.4 (98/1810) [11]
Argentina*	18	1269 (10.1)	22 (2.5) [9]	1.7 (22/1269) [15]
Canada*^†	12	1213 (9.7)	101 (11.5) [2]	8.3 (101/1213) [7]
Brazil*^†	9	968 (7.7)	65 (7.4) [4]	6.7 (65/968) [9]
India*	21	803 (6.4)	29 (3.3) [8]	3.6 (29/803) [12]
United States*^†	26	760 (6.1)	206 (23.3) [1]	27.1 (206/760) [2]
Australia*^†	4	667 (5.3)	53 (6.0) [6]	7.9 (53/667) [8]
Malaysia*	4	641 (5.1)	12 (1.4) [11]	1.9 (12/641) [14]
Philippines*	10	489 (3.9)	10 (1.1) [12]	2.0 (10/489) [13]
Mexico*^†	10	475 (3.8)	54 (6.1) [5]	11.4 (54/475) [6]
Belgium^†	7	360 (2.9)	43 (4.9) [7]	11.9 (43/360) [5]
Poland^†	10	210 (1.7)	29 (3.3) [8]	13.8 (29/210) [4]
New Zealand^†	1	145 (1.2)	9 (1.0) [13]	6.2 (9/145) [10]
Turkey^†	16	128 (1.2)	43 (4.9) [7]	33.6 (43/128) [1]
Algeria^†	6	105 (0.8)	19 (2.2) [10]	18.1 (19/105) [3]

* Top 10 enrolling countries.
^† Top 10 countries with highest within-country DrotAA use (enrollment >100 patients)
Numbers in brackets, [], relate to a country's rank for DrotAA patients and within country use
DrotAA = drotrecogin alfa (activated); MODS = multiple organ dysfunction syndrome; PROGRESS = Promoting Global Research Excellence in Severe Sepsis.

ISSN: 1364-8535